The global bile duct cancer market is likely to grow at a 9.2% CAGR between 2017- 2023,
according to the recent Market Research Future (MRFR) report. Bile duct cancer is a form of
cancer that occurs in the slender tubes which carry bile through the liver. It is a rare yet
aggressive type of cancer. Some of its symptoms include nausea and vomiting, fever, loss of
appetite, weight loss, abdominal pain, dark urine, light-colored stools, jaundice, and
intensely itchy skin.
Various factors are adding to the global bile duct cancer market share. These factors, as per
the new MRFR report, include increasing cases of bile duct cancer, rising healthcare
expenditures, rising awareness of bile duct cancer, increasing investments in the research
and development activities for treatment procedures, and technological advances in the
Request Sample Copy:
On the contrary, high treatment costs, long duration in drug approvals, low healthcare
expenditure, and related side effects are factors that may limit the bile duct cancer market
growth over the forecast period.
The MRFR report provides an inclusive segmental analysis of the global bile duct cancer
market based on end users, type, treatment, and diagnosis.
By type, the bile duct cancer market is segmented into extrahepatic, intrahepatic, and
By diagnosis, the bile duct cancer market is segmented into surgery, abdominal imaging,
blood tests, and others. The abdominal imaging segment is again segmented into magnetic
resonance cholangiopancreatography (MRCP), percutaneous transhepatic cholangiography
(PTC), endoscopic retrograde cholangiopancreatography (ERCP), and others.
By treatment, the bile duct cancer market is segmented into radiotherapy, chemotherapy,
and others. The chemotherapy segment is again segmented into cisplatin, gemcitabine, 5-
fluorouracil, and others. Of these, the 5-fluorouracil segment will le